David R Grimm, Daniel M Beswick, Sabrina L Maoz, Eric W Wang, Garret W Choby, Edward C Kuan, Erik P Chan, Nithin D Adappa, Mathew Geltzeiler, Anne E Getz, Ian M Humphreys, Christopher H Le, Waleed M Abuzeid, Eugene H Chang, Aria Jafari, Todd T Kingdom, Michael A Kohanski, Jivianne K Lee, Jayakar V Nayak, James N Palmer, Zara M Patel, Carlos D Pinheiro-Neto, Adam C Resnick, Myung S Sim, Timothy L Smith, Carl H Snyderman, Maie A John, Phillip Storm, Jeffrey D Suh, Marilene B Wang, Peter H Hwang
BACKGROUND: Patients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22-item Sinonasal Outcomes Test (SNOT-22) has been shown to improve with treatment. This study aims to characterize SNOT-22 subdomain outcomes in SNM. METHODS: Patients diagnosed with SNM were prospectively enrolled in a multi-center patient registry. SNOT-22 scores were collected at the time of diagnosis and through the post-treatment period for up to 5 years...
February 19, 2024: International Forum of Allergy & Rhinology